↓ Skip to main content

Desmopressin in Mild Hemophilia A: Indications, Limitations, Efficacy, and Safety

Overview of attention for article published in Seminars in Thrombosis & Hemostasis, January 2003
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
23 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Desmopressin in Mild Hemophilia A: Indications, Limitations, Efficacy, and Safety
Published in
Seminars in Thrombosis & Hemostasis, January 2003
DOI 10.1055/s-2003-37944
Pubmed ID
Authors

Stefan Lethagen

Abstract

Replacement therapy with blood products has long been the only available therapeutic option for patients with bleeding disorders. Plasma-derived cryoprecipitate and factor (F) VIII concentrates, which have been used for hemophilia A patients, involve the risk of transmitting blood-borne diseases. Both plasma-derived and recombinant FVIII concentrates are expensive, and there is a global shortage. The synthetic vasopressin analogue desmopressin acetate (1-deamino-[8-D-arginine]-vasopressin, DDAVP) increases plasma concentrations of coagulation FVIII and von Willebrand factor (vWF) two fold to six fold through endogenous release. The drug is an attractive therapeutic alternative because it carries no risk of transmission of infectious diseases. Desmopressin is today a widely used hemostatic agent not only in patients with mild hemophilia A or von Willebrand disease (vWD) but also in those with congenital or acquired platelet dysfunction. There is a long clinical experience with the drug because it has been used for prevention of bleedings in connection with invasive procedures and for treatment of bleedings since the mid-1970s. Not all hemophilia A patients can be treated. The clinical usefulness depends on the postdesmopressin plasma concentration of FVIII, which in turn depends on the patient's basal FVIII level. Therefore, a test dose is recommended in candidate patients. In general, only the mildest hemophilia A patients respond sufficiently. Optimal hemostatic effect is achieved with a dosage of 0.3 microg/kg given intravenously. An intranasal desmopressin spray is suitable for the home treatment.

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 4%
Canada 1 4%
Unknown 21 91%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 26%
Other 4 17%
Student > Postgraduate 2 9%
Professor 2 9%
Student > Bachelor 1 4%
Other 6 26%
Unknown 2 9%
Readers by discipline Count As %
Medicine and Dentistry 14 61%
Agricultural and Biological Sciences 1 4%
Nursing and Health Professions 1 4%
Biochemistry, Genetics and Molecular Biology 1 4%
Immunology and Microbiology 1 4%
Other 3 13%
Unknown 2 9%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 April 2015.
All research outputs
#10,953,145
of 12,359,847 outputs
Outputs from Seminars in Thrombosis & Hemostasis
#494
of 561 outputs
Outputs of similar age
#194,420
of 235,333 outputs
Outputs of similar age from Seminars in Thrombosis & Hemostasis
#8
of 8 outputs
Altmetric has tracked 12,359,847 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 561 research outputs from this source. They receive a mean Attention Score of 3.5. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,333 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one.